Table 2a Survival analyses for use of combination vs single agent regimens in the first-line settings

From: Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review

  

Model A/months (95% confidence interval)

P -value

Model B/HR (95% confidence interval)

P -value

First-line combination

mPFS

8.4 (6.9–9.8)

0·007

0.48 (0.41–0.56)

<0.0001

First-line single agent

 

3.5 (1.1–5.9)

   

First-line combination

mOS

17.8 (14.2–21.4)

0·020

1.16 (0.98–1.38)

0.084

First-line single agent

 

8.2 (0.0–16.7)

   
  1. Abbreviations: HR=hazard ratio, mOS=median overall survival, mPFS=median progression-free survival.
Back to article page